AXGN:NASDAQ
AxoGen, Inc Common Stock
$43.36
arrow_downward
-0.07%(-0.030) 1D
$43.72
arrow_upward
+0.83% (+0.36)todayPre-market
Closed: Sep 28, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
$43.23
High
$43.94
Low
$42.46
Mkt. cap
2.54B
Avg. vol.
1.15M
Volume
17.00
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.16
Shares outstanding
58.67M
No. of employees
622
Open
$43.23
High
$43.94
Low
$42.46
Mkt. cap
2.54B
Avg. vol.
1.15M
Volume
17.00
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.16
Shares outstanding
58.67M
No. of employees
622
News stories
From web sources and news partners
Simply Wall Street
·
11 hours ago
What Is Drawing Attention To Axogen (AXGN)?
https://www.dars.gov.et/
·
2 months ago
AXGN Q1 2026 Earnings: EPS Slightly Misses Estimates, Stock Rises Modestly - Product Revenue Analysis
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorMedical device
Websiteaxogeninc.com